Caroline Huber, MPH
Associate Director, Policy & Economics
Caroline Huber has expertise in health policy and scientific communication across a range of therapeutic and topic areas, including infectious diseases, oncology, and geographic disparities in healthcare. Her work at PHE primarily focuses on quality of care and the value of therapeutic innovations to patients and society. She has experience in both qualitative and quantitative research methods, including literature-based and epidemiological models, literature reviews, and in-depth interviews.
MPH, Columbia University
BS, Industrial and Labor Relations, Cornell University
- Moreno GA, et al. Costs and spillover effects of private insurers’ coverage of hepatitis C treatment. Am J Manag Care. 2016.
- Saab S, et al. Cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir+ribavirin for US post-liver transplant recurrent genotype 1 HCV. Liver Int. 2016.
- Shafrin J, et al. Effects of delay in the adoption of cancer innovation: case studies of six landmark medications. J Clin Oncol. 2017.
- Shafrin J, et al. Geographic variation in diagnostic ability and quality of care metrics: a case study of ankylosing spondylitis and low back pain. Inquiry. 2017.